Key Highlights
- Kestra Medical Technologies (NASDAQ: KMTS) closed a $200 million senior secured term loan facility with Pharmakon Advisors-managed funds.
- The initial $75 million tranche was funded on July 10, 2026, with additional drawdowns tied to revenue milestones.
- Interest rates are set at 5.50% plus three-month SOFR, with a 3.25% floor, and a 1.75% upfront fee.
- The company must maintain minimum liquidity of $20 million under the agreement.
Loan Facility Announced
Kestra Medical Technologies (NASDAQ: KMTS) has finalized a $200 million senior secured term loan facility with investment funds managed by Pharmakon Advisors. The agreement, disclosed in a regulatory filing, provides a five-year financing structure to support corporate expansion and working capital needs. The facility replaces a prior loan arrangement terminated in connection with the new deal.
Funding Structure Breakdown
The facility is divided into four tranches, with the first $75 million tranche funded immediately on July 10, 2026. A second $25 million tranche is available at the company’s discretion through July 31, 2027, subject to conditions. A $50 million tranche becomes accessible once Kestra Medical achieves trailing twelve-month revenue of $150 million, with a deadline of June 30, 2028.
An additional $50 million uncommitted tranche is reserved for potential acquisitions. Borrowers must pay a 1.75% fee on the total committed amount at each tranche’s funding. Interest payments are due quarterly, beginning after the initial closing date, with 48 months of interest-only payments.
Principal amortization starts in the second fiscal quarter of 2030, continuing through the July 10, 2031 maturity.
Collateral and Covenants
The agreement grants lenders a security interest in nearly all of Kestra Medical’s assets, including intellectual property. The company must maintain minimum liquidity of $20 million in cash and equivalents at all times. Restrictive covenants limit additional debt, dividend payments, and mergers without lender approval.
Affirmative covenants require compliance with laws, insurance maintenance, and regulatory adherence.
Prior Loan Termination
The new facility replaces a previous loan agreement entered on September 29, 2023, with Perceptive Credit Holdings. The prior loan was fully repaid and terminated upon closing the new deal, releasing all associated security interests. The transition provides Kestra Medical with a larger capital base and extended repayment terms.
Use of Proceeds
Funds from the facility will primarily support general corporate purposes and working capital requirements. The uncommitted $50 million tranche offers flexibility for strategic acquisitions, though drawdowns require lender approval. The structure aligns with Kestra Medical’s growth trajectory in the medical technology sector.
Financial Reporting Context
The loan agreement was disclosed alongside Kestra Medical’s fiscal quarter results for the period ended April 30, 2026. The company issued a press release on July 14, 2026, detailing its financial performance, though the loan terms were not highlighted in that announcement.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...